Change of clinical management through serial FDG-PET/CT in patients with FDG-positive adverse events under immunotherapy

Conclusions: In combinational immunotherapy more than 60% of the pts develop AE. FDG avidity of the affected organs has the potential to noninvasively monitor inflammatory reaction and therefore might prove helpful in 28% of these patients to alter clinical decisions for therapy continuation.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Mustafa, M., Zhuwu, Y., Krackhardt, A., Nekolla, S., Schwaiger, M., Weber, W. Tags: Sarcoma/ Melanoma Source Type: research